Question Description
Directions: Read the following passage and answer the question.For decades, frustrated neurologists had nothing but palliative care to offer as the grey matter covering the brain degenerated progressively in patients with Alzheimer's disease. First identified in 1906, the cognitive disorder has been one of the most difficult challenges for healthcare systems globally. The failure rate of drugs to combat it is 99.6 per cent — for cancer, this rate is around 81 per cent. That's why the result of clinical trials of lecanemab, a new drug developed by pharma companies Biogen and Eisai, has generated hope. The two companies announced that the drug slowed down the rate of memory and thinking decline in Alzheimer's patients by 27 per cent. This might seem a modest rate but this is the first time a drug has shown the potential to slow down the onset of dementia.Lecanemab is an antibody that cleans protein deposits on brain cells, believed by a section of scientists to cause cognitive impairments. Not only did lecanemab clear the amyloid build-up in the brain cells of participants in the 18-month long trial, it also demonstrated a significant effect on their cognitive functions.More than 50 million people have Alzheimer's worldwide. In the past 20 years, mortality caused by the disease has shot up by more than 120 per cent. Experts believe that these figures do not depict the true extent of the healthcare problem. In many parts of the world, dementia is seen as a fallout of the ageing process and people do not seek medical care. But research has shown that in a large number of cases, the illness begins in the mid to late forties. That's why drug candidates like lecanemab could hold the key in the battle against Alzheimer's.[Extracted with edits and revisions, from Editorials, The Indian Express, dated Oct 1, 2022]Q. Which of the following is the central theme of the given passage?a)Making new medicines affordable to all and spreading general knowledge about Alzheimer's disease are imperatives.b)Alzheimer's disease is taken as the consequence of progressive pathological changes in grey matter.c)A new drug and consciousness among people can prove to be effective against Alzheimer's disease.d)Dementia is more common than previously recognised, with more than 50% of people diagnosed with Alzheimer's disease.Correct answer is option 'C'. Can you explain this answer? for CLAT 2025 is part of CLAT preparation. The Question and answers have been prepared according to the CLAT exam syllabus. Information about Directions: Read the following passage and answer the question.For decades, frustrated neurologists had nothing but palliative care to offer as the grey matter covering the brain degenerated progressively in patients with Alzheimer's disease. First identified in 1906, the cognitive disorder has been one of the most difficult challenges for healthcare systems globally. The failure rate of drugs to combat it is 99.6 per cent — for cancer, this rate is around 81 per cent. That's why the result of clinical trials of lecanemab, a new drug developed by pharma companies Biogen and Eisai, has generated hope. The two companies announced that the drug slowed down the rate of memory and thinking decline in Alzheimer's patients by 27 per cent. This might seem a modest rate but this is the first time a drug has shown the potential to slow down the onset of dementia.Lecanemab is an antibody that cleans protein deposits on brain cells, believed by a section of scientists to cause cognitive impairments. Not only did lecanemab clear the amyloid build-up in the brain cells of participants in the 18-month long trial, it also demonstrated a significant effect on their cognitive functions.More than 50 million people have Alzheimer's worldwide. In the past 20 years, mortality caused by the disease has shot up by more than 120 per cent. Experts believe that these figures do not depict the true extent of the healthcare problem. In many parts of the world, dementia is seen as a fallout of the ageing process and people do not seek medical care. But research has shown that in a large number of cases, the illness begins in the mid to late forties. That's why drug candidates like lecanemab could hold the key in the battle against Alzheimer's.[Extracted with edits and revisions, from Editorials, The Indian Express, dated Oct 1, 2022]Q. Which of the following is the central theme of the given passage?a)Making new medicines affordable to all and spreading general knowledge about Alzheimer's disease are imperatives.b)Alzheimer's disease is taken as the consequence of progressive pathological changes in grey matter.c)A new drug and consciousness among people can prove to be effective against Alzheimer's disease.d)Dementia is more common than previously recognised, with more than 50% of people diagnosed with Alzheimer's disease.Correct answer is option 'C'. Can you explain this answer? covers all topics & solutions for CLAT 2025 Exam. Find important definitions, questions, meanings, examples, exercises and tests below for Directions: Read the following passage and answer the question.For decades, frustrated neurologists had nothing but palliative care to offer as the grey matter covering the brain degenerated progressively in patients with Alzheimer's disease. First identified in 1906, the cognitive disorder has been one of the most difficult challenges for healthcare systems globally. The failure rate of drugs to combat it is 99.6 per cent — for cancer, this rate is around 81 per cent. That's why the result of clinical trials of lecanemab, a new drug developed by pharma companies Biogen and Eisai, has generated hope. The two companies announced that the drug slowed down the rate of memory and thinking decline in Alzheimer's patients by 27 per cent. This might seem a modest rate but this is the first time a drug has shown the potential to slow down the onset of dementia.Lecanemab is an antibody that cleans protein deposits on brain cells, believed by a section of scientists to cause cognitive impairments. Not only did lecanemab clear the amyloid build-up in the brain cells of participants in the 18-month long trial, it also demonstrated a significant effect on their cognitive functions.More than 50 million people have Alzheimer's worldwide. In the past 20 years, mortality caused by the disease has shot up by more than 120 per cent. Experts believe that these figures do not depict the true extent of the healthcare problem. In many parts of the world, dementia is seen as a fallout of the ageing process and people do not seek medical care. But research has shown that in a large number of cases, the illness begins in the mid to late forties. That's why drug candidates like lecanemab could hold the key in the battle against Alzheimer's.[Extracted with edits and revisions, from Editorials, The Indian Express, dated Oct 1, 2022]Q. Which of the following is the central theme of the given passage?a)Making new medicines affordable to all and spreading general knowledge about Alzheimer's disease are imperatives.b)Alzheimer's disease is taken as the consequence of progressive pathological changes in grey matter.c)A new drug and consciousness among people can prove to be effective against Alzheimer's disease.d)Dementia is more common than previously recognised, with more than 50% of people diagnosed with Alzheimer's disease.Correct answer is option 'C'. Can you explain this answer?.

Solutions for Directions: Read the following passage and answer the question.For decades, frustrated neurologists had nothing but palliative care to offer as the grey matter covering the brain degenerated progressively in patients with Alzheimer's disease. First identified in 1906, the cognitive disorder has been one of the most difficult challenges for healthcare systems globally. The failure rate of drugs to combat it is 99.6 per cent — for cancer, this rate is around 81 per cent. That's why the result of clinical trials of lecanemab, a new drug developed by pharma companies Biogen and Eisai, has generated hope. The two companies announced that the drug slowed down the rate of memory and thinking decline in Alzheimer's patients by 27 per cent. This might seem a modest rate but this is the first time a drug has shown the potential to slow down the onset of dementia.Lecanemab is an antibody that cleans protein deposits on brain cells, believed by a section of scientists to cause cognitive impairments. Not only did lecanemab clear the amyloid build-up in the brain cells of participants in the 18-month long trial, it also demonstrated a significant effect on their cognitive functions.More than 50 million people have Alzheimer's worldwide. In the past 20 years, mortality caused by the disease has shot up by more than 120 per cent. Experts believe that these figures do not depict the true extent of the healthcare problem. In many parts of the world, dementia is seen as a fallout of the ageing process and people do not seek medical care. But research has shown that in a large number of cases, the illness begins in the mid to late forties. That's why drug candidates like lecanemab could hold the key in the battle against Alzheimer's.[Extracted with edits and revisions, from Editorials, The Indian Express, dated Oct 1, 2022]Q. Which of the following is the central theme of the given passage?a)Making new medicines affordable to all and spreading general knowledge about Alzheimer's disease are imperatives.b)Alzheimer's disease is taken as the consequence of progressive pathological changes in grey matter.c)A new drug and consciousness among people can prove to be effective against Alzheimer's disease.d)Dementia is more common than previously recognised, with more than 50% of people diagnosed with Alzheimer's disease.Correct answer is option 'C'. Can you explain this answer? in English & in Hindi are available as part of our courses for CLAT. Download more important topics, notes, lectures and mock test series for CLAT Exam by signing up for free.

Here you can find the meaning of Directions: Read the following passage and answer the question.For decades, frustrated neurologists had nothing but palliative care to offer as the grey matter covering the brain degenerated progressively in patients with Alzheimer's disease. First identified in 1906, the cognitive disorder has been one of the most difficult challenges for healthcare systems globally. The failure rate of drugs to combat it is 99.6 per cent — for cancer, this rate is around 81 per cent. That's why the result of clinical trials of lecanemab, a new drug developed by pharma companies Biogen and Eisai, has generated hope. The two companies announced that the drug slowed down the rate of memory and thinking decline in Alzheimer's patients by 27 per cent. This might seem a modest rate but this is the first time a drug has shown the potential to slow down the onset of dementia.Lecanemab is an antibody that cleans protein deposits on brain cells, believed by a section of scientists to cause cognitive impairments. Not only did lecanemab clear the amyloid build-up in the brain cells of participants in the 18-month long trial, it also demonstrated a significant effect on their cognitive functions.More than 50 million people have Alzheimer's worldwide. In the past 20 years, mortality caused by the disease has shot up by more than 120 per cent. Experts believe that these figures do not depict the true extent of the healthcare problem. In many parts of the world, dementia is seen as a fallout of the ageing process and people do not seek medical care. But research has shown that in a large number of cases, the illness begins in the mid to late forties. That's why drug candidates like lecanemab could hold the key in the battle against Alzheimer's.[Extracted with edits and revisions, from Editorials, The Indian Express, dated Oct 1, 2022]Q. Which of the following is the central theme of the given passage?a)Making new medicines affordable to all and spreading general knowledge about Alzheimer's disease are imperatives.b)Alzheimer's disease is taken as the consequence of progressive pathological changes in grey matter.c)A new drug and consciousness among people can prove to be effective against Alzheimer's disease.d)Dementia is more common than previously recognised, with more than 50% of people diagnosed with Alzheimer's disease.Correct answer is option 'C'. Can you explain this answer? defined & explained in the simplest way possible. Besides giving the explanation of Directions: Read the following passage and answer the question.For decades, frustrated neurologists had nothing but palliative care to offer as the grey matter covering the brain degenerated progressively in patients with Alzheimer's disease. First identified in 1906, the cognitive disorder has been one of the most difficult challenges for healthcare systems globally. The failure rate of drugs to combat it is 99.6 per cent — for cancer, this rate is around 81 per cent. That's why the result of clinical trials of lecanemab, a new drug developed by pharma companies Biogen and Eisai, has generated hope. The two companies announced that the drug slowed down the rate of memory and thinking decline in Alzheimer's patients by 27 per cent. This might seem a modest rate but this is the first time a drug has shown the potential to slow down the onset of dementia.Lecanemab is an antibody that cleans protein deposits on brain cells, believed by a section of scientists to cause cognitive impairments. Not only did lecanemab clear the amyloid build-up in the brain cells of participants in the 18-month long trial, it also demonstrated a significant effect on their cognitive functions.More than 50 million people have Alzheimer's worldwide. In the past 20 years, mortality caused by the disease has shot up by more than 120 per cent. Experts believe that these figures do not depict the true extent of the healthcare problem. In many parts of the world, dementia is seen as a fallout of the ageing process and people do not seek medical care. But research has shown that in a large number of cases, the illness begins in the mid to late forties. That's why drug candidates like lecanemab could hold the key in the battle against Alzheimer's.[Extracted with edits and revisions, from Editorials, The Indian Express, dated Oct 1, 2022]Q. Which of the following is the central theme of the given passage?a)Making new medicines affordable to all and spreading general knowledge about Alzheimer's disease are imperatives.b)Alzheimer's disease is taken as the consequence of progressive pathological changes in grey matter.c)A new drug and consciousness among people can prove to be effective against Alzheimer's disease.d)Dementia is more common than previously recognised, with more than 50% of people diagnosed with Alzheimer's disease.Correct answer is option 'C'. Can you explain this answer?, a detailed solution for Directions: Read the following passage and answer the question.For decades, frustrated neurologists had nothing but palliative care to offer as the grey matter covering the brain degenerated progressively in patients with Alzheimer's disease. First identified in 1906, the cognitive disorder has been one of the most difficult challenges for healthcare systems globally. The failure rate of drugs to combat it is 99.6 per cent — for cancer, this rate is around 81 per cent. That's why the result of clinical trials of lecanemab, a new drug developed by pharma companies Biogen and Eisai, has generated hope. The two companies announced that the drug slowed down the rate of memory and thinking decline in Alzheimer's patients by 27 per cent. This might seem a modest rate but this is the first time a drug has shown the potential to slow down the onset of dementia.Lecanemab is an antibody that cleans protein deposits on brain cells, believed by a section of scientists to cause cognitive impairments. Not only did lecanemab clear the amyloid build-up in the brain cells of participants in the 18-month long trial, it also demonstrated a significant effect on their cognitive functions.More than 50 million people have Alzheimer's worldwide. In the past 20 years, mortality caused by the disease has shot up by more than 120 per cent. Experts believe that these figures do not depict the true extent of the healthcare problem. In many parts of the world, dementia is seen as a fallout of the ageing process and people do not seek medical care. But research has shown that in a large number of cases, the illness begins in the mid to late forties. That's why drug candidates like lecanemab could hold the key in the battle against Alzheimer's.[Extracted with edits and revisions, from Editorials, The Indian Express, dated Oct 1, 2022]Q. Which of the following is the central theme of the given passage?a)Making new medicines affordable to all and spreading general knowledge about Alzheimer's disease are imperatives.b)Alzheimer's disease is taken as the consequence of progressive pathological changes in grey matter.c)A new drug and consciousness among people can prove to be effective against Alzheimer's disease.d)Dementia is more common than previously recognised, with more than 50% of people diagnosed with Alzheimer's disease.Correct answer is option 'C'. Can you explain this answer? has been provided alongside types of Directions: Read the following passage and answer the question.For decades, frustrated neurologists had nothing but palliative care to offer as the grey matter covering the brain degenerated progressively in patients with Alzheimer's disease. First identified in 1906, the cognitive disorder has been one of the most difficult challenges for healthcare systems globally. The failure rate of drugs to combat it is 99.6 per cent — for cancer, this rate is around 81 per cent. That's why the result of clinical trials of lecanemab, a new drug developed by pharma companies Biogen and Eisai, has generated hope. The two companies announced that the drug slowed down the rate of memory and thinking decline in Alzheimer's patients by 27 per cent. This might seem a modest rate but this is the first time a drug has shown the potential to slow down the onset of dementia.Lecanemab is an antibody that cleans protein deposits on brain cells, believed by a section of scientists to cause cognitive impairments. Not only did lecanemab clear the amyloid build-up in the brain cells of participants in the 18-month long trial, it also demonstrated a significant effect on their cognitive functions.More than 50 million people have Alzheimer's worldwide. In the past 20 years, mortality caused by the disease has shot up by more than 120 per cent. Experts believe that these figures do not depict the true extent of the healthcare problem. In many parts of the world, dementia is seen as a fallout of the ageing process and people do not seek medical care. But research has shown that in a large number of cases, the illness begins in the mid to late forties. That's why drug candidates like lecanemab could hold the key in the battle against Alzheimer's.[Extracted with edits and revisions, from Editorials, The Indian Express, dated Oct 1, 2022]Q. Which of the following is the central theme of the given passage?a)Making new medicines affordable to all and spreading general knowledge about Alzheimer's disease are imperatives.b)Alzheimer's disease is taken as the consequence of progressive pathological changes in grey matter.c)A new drug and consciousness among people can prove to be effective against Alzheimer's disease.d)Dementia is more common than previously recognised, with more than 50% of people diagnosed with Alzheimer's disease.Correct answer is option 'C'. Can you explain this answer? theory, EduRev gives you an ample number of questions to practice Directions: Read the following passage and answer the question.For decades, frustrated neurologists had nothing but palliative care to offer as the grey matter covering the brain degenerated progressively in patients with Alzheimer's disease. First identified in 1906, the cognitive disorder has been one of the most difficult challenges for healthcare systems globally. The failure rate of drugs to combat it is 99.6 per cent — for cancer, this rate is around 81 per cent. That's why the result of clinical trials of lecanemab, a new drug developed by pharma companies Biogen and Eisai, has generated hope. The two companies announced that the drug slowed down the rate of memory and thinking decline in Alzheimer's patients by 27 per cent. This might seem a modest rate but this is the first time a drug has shown the potential to slow down the onset of dementia.Lecanemab is an antibody that cleans protein deposits on brain cells, believed by a section of scientists to cause cognitive impairments. Not only did lecanemab clear the amyloid build-up in the brain cells of participants in the 18-month long trial, it also demonstrated a significant effect on their cognitive functions.More than 50 million people have Alzheimer's worldwide. In the past 20 years, mortality caused by the disease has shot up by more than 120 per cent. Experts believe that these figures do not depict the true extent of the healthcare problem. In many parts of the world, dementia is seen as a fallout of the ageing process and people do not seek medical care. But research has shown that in a large number of cases, the illness begins in the mid to late forties. That's why drug candidates like lecanemab could hold the key in the battle against Alzheimer's.[Extracted with edits and revisions, from Editorials, The Indian Express, dated Oct 1, 2022]Q. Which of the following is the central theme of the given passage?a)Making new medicines affordable to all and spreading general knowledge about Alzheimer's disease are imperatives.b)Alzheimer's disease is taken as the consequence of progressive pathological changes in grey matter.c)A new drug and consciousness among people can prove to be effective against Alzheimer's disease.d)Dementia is more common than previously recognised, with more than 50% of people diagnosed with Alzheimer's disease.Correct answer is option 'C'. Can you explain this answer? tests, examples and also practice CLAT tests.